



April 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2013-004139-62/ Novartis Protocol ID CRAD001JES13

A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of Everolimus plus letrozole in the first line treatment of postmenopausal women with hormone positive metastatic or locally advanced breast cancer

Trial CRAD001JES13 was cancelled with no patient enrollment and as such, no results will be reported.